In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CanBas Co., Ltd.

http://www.canbas.co.jp/

Latest From CanBas Co., Ltd.

Freeline Evaluating Options After No Home Run For Hem B Gene Therapy

Freeline’s FLT180a could still prove to be the best-in-class gene therapy for hemophilia B but its cash and time are running out as rivals grow closer to market.

Blood & Coagulation Disorders Companies

Encouraging Biomarker Data Lift UniQure’s Huntington’s Disease Hopes

Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.

Companies Clinical Trials

Real World Evidence Undercuts Value Of Hereditary Angioedema Drugs In ICER Analysis Update

But results of the re-analysis of three HAE treatments aren’t necessarily expected to be typical for RWE-based updates undertaken in the future by the Institute for Clinical and Economic Review.

Real-World Evidence Health Technology Assessment

Positive Phase II for Polaris lead product in mesothelioma

Privately held biopharmaceutical firm Polaris Group has reported positive Phase II results for its lead product, anticancer ADI-PEG 20, in malignant pleural mesothelioma (MPM), what looks to be its second indication.

Cancer Australia
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register